FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Trial details
- Registry ID
- NCT06788990
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCNCT06788990 | Bicara Therapeutics | Phase 2, Phase 3 | Recruiting | 2028-04Estimated |
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.NCT07365319 | Eikon Therapeutics | Phase 2, Phase 3 | Recruiting | 2035-12-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |